433 MHz Active RFID L-Series Reader for Healthcare Asset Tracking

Toronto, Canada - GAO RFID Asset Tracking (www.GAORFIDAssetTracking.com) is offering its 433 MHz active RFID L-Series reader with RS232 for healthcare asset tracking. This RFID reader is designed for tracking of assets and is widely used in manufacturing, physical distribution and personnel management. This 433 MHz active RFID L-series reader, model 214013, features a compact size and a low current consumption of less than 8 mA. It detects the presence of all L-series compatible active tags within its read range and continuously streams the data to the serial port. It has an internal on-board antenna and can operate in rugged conditions at ranges of up to 15 m. This reader provides an output data baud rate of 57600 bps. The data from detected tags is sent to the recipient device or computer by the reader via RS232 interface, which additionally powers the device so no external power is needed. This 433 MHz active RFID L-series reader belongs to GAO's family of Healthcare Asset Tracking Readers. The family provides a variety of RFID readers such as 433 MHz Active RFID L-Series Reader with Ethernet, 13.56 MHz. High Frequency (HF) SD Interface RFID Reader, 13.56MHz RFID HF Bluetooth Reader/Writer which is widely used in the industries of security / patrol / mining / finance and railway system, and many other similar products. The line of products offers GAO's customers valuable choices. GAO has one of the broadest portfolios of RFID readers and tags in the industry. For sales inquiries please contact: 1-877 585-9555 ext. 601 - Toll Free (USA & Canada) 1-416 292-0038 ext. 601 - All Other Areas [email protected] About GAO RFID Asset Tracking GAO RFID Asset Tracking (www.GAORFIDAssetTracking.com) is known for having one of the largest RFID tag and reader lines in the RFID product industry. GAO RFID Asset Tracking's products have been widely used in fields such as personnel access control, asset tracking, logistics and warehouse management. GAO RFID will be exhibiting at the RFID Journal LIVE! Conference and Exhibition. Visit Us at Booth 116.

Suggested Articles

Reata’s bardoxolone improved kidney function in a phase 3 trial of patients with a rare form of chronic kidney disease.

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.